TY - JOUR
T1 - Gastrointestinal stromal tumours
T2 - Origin and molecular oncology
AU - Corless, Christopher L.
AU - Barnett, Christine M.
AU - Heinrich, Michael C.
N1 - Funding Information:
The authors wish to acknowledge all of the members of their laboratories for their continuing efforts on gastrointestinal stromal tumour (GIST) research. Some of the work referenced in this article was supported by generous donations from the GIST Cancer Research Fund and the BP Lester Foundation, and by grant support from the LifeRaft Group. In addition, M.C.H. received research grant funding from the Department of Veterans Affairs (Merit Review Award).
PY - 2011/12
Y1 - 2011/12
N2 - Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of personalized treatment for cancer patients. The nearly simultaneous discovery of a biomarker that is reflective of their origin and the presence of gain-of-function kinase mutations in these tumours set the stage for more accurate diagnosis and the development of kinase inhibitor therapy. Subsequent studies of genotype and phenotype have led to a molecular classification of GIST and to treatment optimization on the basis of molecular subtype. The study of drug-resistant tumours has advanced our understanding of kinase biology, enabling the development of novel kinase inhibitors. Further improvements in GIST treatment may require targeting GIST stem cell populations and/or additional genomic events.
AB - Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of personalized treatment for cancer patients. The nearly simultaneous discovery of a biomarker that is reflective of their origin and the presence of gain-of-function kinase mutations in these tumours set the stage for more accurate diagnosis and the development of kinase inhibitor therapy. Subsequent studies of genotype and phenotype have led to a molecular classification of GIST and to treatment optimization on the basis of molecular subtype. The study of drug-resistant tumours has advanced our understanding of kinase biology, enabling the development of novel kinase inhibitors. Further improvements in GIST treatment may require targeting GIST stem cell populations and/or additional genomic events.
UR - http://www.scopus.com/inward/record.url?scp=81855226071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81855226071&partnerID=8YFLogxK
U2 - 10.1038/nrc3143
DO - 10.1038/nrc3143
M3 - Review article
C2 - 22089421
AN - SCOPUS:81855226071
SN - 1474-175X
VL - 11
SP - 865
EP - 878
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 12
ER -